Elevance Health Q1 EPS Forecast Decreased by Zacks Research

Elevance Health, Inc. (NYSE:ELV) – Equities researchers at Zacks Research dropped their Q1 2025 earnings per share estimates for Elevance Health in a report released on Wednesday, December 18th. Zacks Research analyst K. Dey now forecasts that the company will post earnings of $10.76 per share for the quarter, down from their previous estimate of $10.87. The consensus estimate for Elevance Health’s current full-year earnings is $32.96 per share.

Other analysts have also issued reports about the stock. TD Cowen reduced their price target on shares of Elevance Health from $589.00 to $484.00 and set a “buy” rating for the company in a research note on Monday, October 21st. Barclays cut their target price on Elevance Health from $622.00 to $501.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Cantor Fitzgerald decreased their price target on Elevance Health from $600.00 to $485.00 and set an “overweight” rating for the company in a research note on Friday, October 18th. Mizuho dropped their price objective on Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company decreased their target price on Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and an average price target of $539.20.

Elevance Health Stock Performance

Shares of ELV opened at $366.48 on Friday. The firm has a market capitalization of $85.00 billion, a PE ratio of 13.36, a P/E/G ratio of 1.15 and a beta of 0.83. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $412.42 and a 200 day moving average price of $490.27. Elevance Health has a 52-week low of $362.21 and a 52-week high of $567.26.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.66 by ($1.29). The business had revenue of $44.72 billion for the quarter, compared to analyst estimates of $43.47 billion. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm posted $8.99 EPS.

Institutional Investors Weigh In On Elevance Health

Hedge funds have recently bought and sold shares of the business. Atria Wealth Solutions Inc. lifted its position in shares of Elevance Health by 5.0% in the second quarter. Atria Wealth Solutions Inc. now owns 5,391 shares of the company’s stock worth $2,921,000 after purchasing an additional 258 shares in the last quarter. Van Lanschot Kempen Investment Management N.V. lifted its position in Elevance Health by 36.3% in the 2nd quarter. Van Lanschot Kempen Investment Management N.V. now owns 10,748 shares of the company’s stock worth $5,824,000 after buying an additional 2,863 shares in the last quarter. Quotient Wealth Partners LLC boosted its stake in shares of Elevance Health by 3.9% during the 2nd quarter. Quotient Wealth Partners LLC now owns 635 shares of the company’s stock valued at $344,000 after buying an additional 24 shares during the period. Atlantic Union Bankshares Corp grew its holdings in shares of Elevance Health by 1,172.5% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 7,253 shares of the company’s stock valued at $3,930,000 after acquiring an additional 6,683 shares in the last quarter. Finally, Banque Pictet & Cie SA grew its holdings in shares of Elevance Health by 6.1% during the 2nd quarter. Banque Pictet & Cie SA now owns 17,653 shares of the company’s stock valued at $9,565,000 after acquiring an additional 1,013 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of Elevance Health stock in a transaction on Friday, October 18th. The stock was sold at an average price of $432.14, for a total transaction of $3,205,182.38. Following the transaction, the executive vice president now owns 8,423 shares in the company, valued at approximately $3,639,915.22. The trade was a 46.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.35% of the stock is owned by company insiders.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 20th. Stockholders of record on Thursday, December 5th will be given a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.78%. The ex-dividend date is Thursday, December 5th. Elevance Health’s dividend payout ratio (DPR) is currently 23.77%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.